- Home
- RGC vs ARQT Comparison
RGC vs ARQT Comparison
Compare RGC & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGC | ARQT |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.5B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RGC | ARQT |
|---|---|---|
| Price | $5.41 | $25.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | 204.6K | ★ 1.5M |
| Earning Date | 10-31-2025 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | N/A | $34.85 |
| Revenue Next Year | N/A | $29.39 |
| P/E Ratio | ★ N/A | $864.33 |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $4.51 | $15.10 |
| 52 Week High | $69.00 | $31.77 |
Technical Indicators
Market Signals| Indicator | RGC | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 36.40 | 46.21 |
| Support Level | $4.51 | $24.96 |
| Resistance Level | $6.53 | $28.35 |
| Average True Range (ATR) | 0.54 | 1.27 |
| MACD | 0.28 | -0.22 |
| Stochastic Oscillator | 26.09 | 27.01 |
Price Performance
Historical ComparisonAbout RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.